CORE D - ABSTRACT The UCSF ADRC Neuropathology, Biospecimens, and Genetics core (NP core, Core D) provides vital research support to the UCSF ADRC and to the neurodegenerative disease research community at UCSF and beyond. Neurodegenerative disease pathology and genetics have become increasingly exciting and complex in recent years, with major advances arising from work accomplished through this ADRC. In this renewal application, the NP Core will continue to be led by Dr. William Seeley. Dr. Lea Grinberg will found a new Biospecimens sub-core, and Drs. Dan Geschwind and Giovanni Coppola will continue to lead the Genetics sub-core at UCLA. The NP Core aims to: (1) Obtain and bank human biomaterial for neuropathological, biochemical, and genetic charaterization;(2) Analyze specimens and document results, including NP diagnoses rendered using current diagnostic consensus criteria, and (3) Enter NP, bioassay, and genetics results into research-oriented databases and distribute specimens. These core functions will support the aims of Projects 1 (EOAD variants), 2 (PPA heterogeneity), and 3 (iPSC models) by providing final neuropathological diagnoses, organizing and conducting biochemical analyses, and providing genotyping and gene expression analysis. Moreover, the NP Core will help to further develop a unique bank of specially handled materials (brain, spinal cord, CSF, plasma, urine, RNA/DNA) for ongoing and future molecular, translational, clinicopathological, and biomarker discovery research.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG023501-11
Application #
8677146
Study Section
Special Emphasis Panel (ZAG1-ZIJ-4 (J1))
Project Start
2014-04-01
Project End
2019-03-31
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
11
Fiscal Year
2014
Total Cost
$360,159
Indirect Cost
$102,507
Name
University of California San Francisco
Department
Type
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Barton, Cynthia; Ketelle, Robin; Merrilees, Jennifer et al. (2016) Non-pharmacological Management of Behavioral Symptoms in Frontotemporal and Other Dementias. Curr Neurol Neurosci Rep 16:14
Rabinovici, Gil D (2016) Amyloid biomarkers: pushing the limits of early detection. Brain 139:1008-10
Mez, Jesse; Mukherjee, Shubhabrata; Thornton, Timothy et al. (2016) The executive prominent/memory prominent spectrum in Alzheimer's disease is highly heritable. Neurobiol Aging 41:115-21
Schott, Jonathan M; Crutch, Sebastian J; Carrasquillo, Minerva M et al. (2016) Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimers Dement 12:862-71
Yokoyama, Jennifer S; Desikan, Rahul S (2016) Association of Alzheimer Disease Susceptibility Variants and Gene Expression in the Human Brain-Reply. JAMA Neurol 73:1255
Voyle, N; Kim, M; Proitsi, P et al. (2016) Blood metabolite markers of neocortical amyloid-β burden: discovery and enrichment using candidate proteins. Transl Psychiatry 6:e719
Mair, Waltraud; Muntel, Jan; Tepper, Katharina et al. (2016) FLEXITau: Quantifying Post-translational Modifications of Tau Protein in Vitro and in Human Disease. Anal Chem 88:3704-14
Oh, Hwamee; Madison, Cindee; Baker, Suzanne et al. (2016) Dynamic relationships between age, amyloid-β deposition, and glucose metabolism link to the regional vulnerability to Alzheimer's disease. Brain 139:2275-89
LoBue, Christian; Denney, David; Hynan, Linda S et al. (2016) Self-Reported Traumatic Brain Injury and Mild Cognitive Impairment: Increased Risk and Earlier Age of Diagnosis. J Alzheimers Dis 51:727-36
Nascimento, Camila; Suemoto, Claudia K; Rodriguez, Roberta D et al. (2016) Higher Prevalence of TDP-43 Proteinopathy in Cognitively Normal Asians: A Clinicopathological Study on a Multiethnic Sample. Brain Pathol 26:177-85

Showing the most recent 10 out of 390 publications